Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
TCAlaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT)

NASDAQ Global Select · Currency in USD
$2.28 ▼ -0.76 (-25.00%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.25 ▼ -0.03 (-1.32%)
After hours: Oct 23, 7:56 PM ET

Summary

Previous Close
$3.04
Open
$2.83
Day's Range
$2.21 – $2.86
52 Week Range
$0.72 – $4.50
Volume
1,323,904
Avg. Volume
4,764,975
Market Cap
$6.67M
Beta (5Y Monthly)
-0.97
PE Ratio (TTM)
--
EPS (TTM)
-$1.65
Earnings Date
Nov 17, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Alaunos Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1
CEO
Holger Weis

Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment.

Earnings

Next report: Tue, Nov 17, 2026
EPS estimate -$15.75
DateEst.Actual
Aug 14, 2026–-$0.41
May 15, 2026–-$0.59
Mar 31, 2026-$3.69-$0.40Beat
Nov 14, 2025-$4.90-$0.55Beat
Aug 14, 2025-$5.33-$0.63Beat
May 15, 2025-$6.44-$0.67Beat

Analyst view

Rating: Hold
Buy 10% · Hold 80% · Sell 10%

Get free alerts on TCRT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.